Scirpa P, Mango D, Liberati M, Manna P, Tartaglia E, Ricci S, Iacona T, Mancuso S
Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy.
Acta Obstet Gynecol Scand. 1988;67(7):589-94. doi: 10.3109/00016348809004269.
The results of hCG stimulation on peripheral levels of androstenedione (A), testosterone (T) and estrone (E1) were examined in 14 patients with ovarian tumors and in 9 tumor-free subjects, after the menopause. Following hCG injection, 9 postmenopausal patients with ovarian tumors showed a significant rise in A peripheral levels. The responsive subjects generally had significant increases in A baseline levels, too. The remaining 5 subjects with advanced or poorly differentiated ovarian cancer with no stroma were not responsive to hCG. Moreover, in the tumor group, 7 subjects had increased baseline T and/or E1 and in 3 of them an increase of these steroids was observed following hCG. In the absence of ovarian tumor, no subject in the control group was responsive to hCG administration. The results of the present investigation seem to confirm the in vivo responsiveness to hCG of ovarian tumors.
对14例卵巢肿瘤患者和9例绝经后无肿瘤受试者，检测了人绒毛膜促性腺激素（hCG）刺激对外周雄烯二酮（A）、睾酮（T）和雌酮（E1）水平的影响。注射hCG后，9例绝经后卵巢肿瘤患者外周血A水平显著升高。有反应的受试者A基线水平通常也有显著升高。其余5例晚期或低分化且无基质的卵巢癌患者对hCG无反应。此外，在肿瘤组中，7例受试者基线T和/或E1升高，其中3例在hCG后观察到这些类固醇增加。在无卵巢肿瘤的情况下，对照组中无受试者对hCG给药有反应。本研究结果似乎证实了卵巢肿瘤对hCG的体内反应性。
